Driving Innovation in Rare Blood Disorders: Jeff Schaffnit’s ASH 2025 Perspective
Jeff Schaffnit, General Manager and Head of Rare Blood Disorders at Sanofi, shared on LinkedIn:
”As I close the chapter on ASH2025, I’m energized by the conversations happening across the hematology community.
Being on the ground at conferences like ASH is so important for our work in rare blood disorders.
It’s where we connect with the researchers advancing the science, the clinicians treating patients every day, and the advocates representing the communities we serve – a convergence of those who have a real stake in the research, the data, and the outcomes.
The breadth of scientific innovation presented this year was impressive.
I heard a lot about the potential of multi-immune modulation as an approach to rare autoimmune conditions like Immune Thrombocytopenia (ITP), warm Autoimmune Hemolytic Anemia (wAIHA), and Sickle Cell Disease (SCD).
While hemophilia remains core to our mission, I’ve enjoyed expanding our scientific discussions with healthcare providers who manage patients with Complex Immune Dysregulation (CID) conditions.
There’s clearly significant room for improvement for these patients who often have no treatments approved specifically for their condition.
These face-to-face conversations remind us why we do what we do.
A red thread throughout all my discussions was how our work translates to real impact in patients’ daily lives.
Hearing directly from the hematology community about the challenges they face, the progress being made, and the work still ahead helps inform our path forward.
What were some of your key learnings from the meeting?”
Stay updated with Hemostasis Today.
-
Sep 8, 2026, 13:26Akhil Santhosh: Closing the Gap in Chemotherapy-Induced Thrombocytopenia
-
Sep 8, 2026, 13:12Roman Rodionov: Is Lp(a) Another Homocysteine?
-
Sep 8, 2026, 12:48Denis Oduor: Beyond the Donation Chair and Into a Legacy of Hope
-
Sep 8, 2026, 12:24Alejandro González Veliz: Can a Stent Cause a Heart Attack?
-
Sep 8, 2026, 11:15Andreas Tridimas: Atherosclerosis Is Greyer Than We Admit
-
Sep 8, 2026, 10:59Eman M. Elsabbagh: Pediatric Nonmalignant HCT Enters the Era of Precision Conditioning and Gene Therapy
-
Sep 8, 2026, 10:50Dena Winchester: Sponsored Genetic Testing Programs Improve Access for Children With Hemophilia A
-
Sep 8, 2026, 10:49Alessandra Bosch: Von Willebrand Disease and Rare Bleeding Disorders, Collaborative Insights and Patient Empowerment
-
Sep 8, 2026, 09:42Vineet Sankhla: Rethinking Potent P2Y12 Inhibition in AF Patients Undergoing PCI